Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study)

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Inflamm Bowel Dis

Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, Hashash JG, Farraye FA

doi: 10.1093/ibd/izae147

Inflammatory Bowel Disease

Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU

United European Gastroenterol J

Madero-Velázquez L, Mínguez A, Mayorga L, Ramírez JJ, Moreno N, Amorós C, Nieto MA, Mena R, Benítez JM, Gimeno-Pitarch L, Maroto N, Suria C, Rodríguez-Moranta F, Ordás I, Ruiz L, García-Brenes MA, Martín-Cardona A, de Célix CR, Cárdenas K, Ginard D, Medina L, Pedrero N, Plaza R, Salmoral R, Martínez-Pérez TJ, Algara V, Merino E, Zabana Y, Gutiérrez A, Young Group of GETECCU

doi: 10.1002/ueg2.12740

Inflammatory Bowel Disease

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU

Gut

Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M, EXIT Study group of GETECCU

doi: 10.1136/gutjnl-2024-333385

Inflammatory Bowel Disease

Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study

J Crohns Colitis

Zhao M, Larsen L, Dige A, Poulsen A, Lo B, Attauabi M, Dige Ovesen P, Wewer MD, Christiansen D, Hvas CL, Petersen AM, Bendtsen F, Seidelin J, Burisch J

doi: 10.1093/ecco-jcc/jjae192

Inflammatory Bowel Disease

Risk of incident cancer in patients with Inflammatory Bowel Disease with prior breast cancer: a multicenter cohort study

Clin Gastroenterol Hepatol

Cosquer GL, Kirchgesner J, Joseph CGS, Seksik P, Amiot A, Laharie D, Nachury M, Rouillon C, Abitbol V, Nuzzo A, Nancey S, Fumery M, Biron A, Richard N, Altwegg R, Moussata D, Caron B, Vidon M, Reenaers C, Uzzan M, Jean-Marie R, Serrero M, Simon M, Benezech A, Goutorbe F, Anne-Laure P, Caillo L, Vaysse C, Poullenot F, getaid

doi: 10.1016/j.cgh.2024.09.034

Inflammatory Bowel Disease

Independent Predictors of 90-Day Readmission in Patients with Inflammatory Bowel Disease: A Nationwide Retrospective Study

J Crohns Colitis

Kunkle B, Singh H, Abraham D, Asamoah N, Barrow J, Mattar M

doi: 10.1093/ecco-jcc/jjaf034

Inflammatory Bowel Disease

Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients

Inflamm Bowel Dis

Uzzan M, Georgiev G, Peyrin-Biroulet L, Bouhnik Y, Narula N, Jairath V, Ungaro R, Burisch J, Kirchgesner J, Verstock B, Hussain F, Reinisch W

doi: 10.1093/ibd/izae233

Inflammatory Bowel Disease

The costs of home monitoring by telemedicine versus standard care for inflammatory bowel diseases - a Danish register-based, five-year follow-up study

J Crohns Colitis

Al-Sheikh M, Ankersen DV, Olsen J, Spanggaard M, Peters-Lehm C, Naimi RM, Bennedsen M, Burisch J, Munkholm P

doi: 10.1093/ecco-jcc/jjae120

Related content

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU

Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study

Risk of incident cancer in patients with Inflammatory Bowel Disease with prior breast cancer: a multicenter cohort study

Independent Predictors of 90-Day Readmission in Patients with Inflammatory Bowel Disease: A Nationwide Retrospective Study

Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients

The costs of home monitoring by telemedicine versus standard care for inflammatory bowel diseases - a Danish register-based, five-year follow-up study